Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) Shares Outstanding (Diluted Average) (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Shares Outstanding (Diluted Average) for 9 consecutive years, with $15.3 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 70.49% to $15.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.3 million through Dec 2025, up 70.49% year-over-year, with the annual reading at $15.3 million for FY2025, 70.49% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $15.3 million at Marker Therapeutics, up from $14.0 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $83.1 million in Q3 2021, with the low at $7.7 million in Q4 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $18.8 million, with a median of $8.9 million recorded in 2024.
  • The sharpest move saw Shares Outstanding (Diluted Average) soared 77.26% in 2021, then crashed 89.96% in 2022.
  • Over 5 years, Shares Outstanding (Diluted Average) stood at $7.7 million in 2021, then grew by 9.16% to $8.4 million in 2022, then increased by 5.49% to $8.8 million in 2023, then grew by 1.94% to $9.0 million in 2024, then soared by 70.49% to $15.3 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $15.3 million, $14.0 million, and $14.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.